Poller B - Search Results

1

Novel insights into bile acid detoxification via CYP, UGT and SULT enzymes.

Kastrinou Lampou V, Poller B, Huth F, Fischer A, Kullak-Ublick GA, Arand M, Schadt HS, Camenisch G. Kastrinou Lampou V, et al. Among authors: poller b. Toxicol In Vitro. 2023 Mar;87:105533. doi: 10.1016/j.tiv.2022.105533. Epub 2022 Dec 5. Toxicol In Vitro. 2023. PMID: 36473578

2

Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects.

Beglinger C, Poller B, Arbit E, Ganzoni C, Gass S, Gomez-Orellana I, Drewe J. Beglinger C, et al. Among authors: poller b. Clin Pharmacol Ther. 2008 Oct;84(4):468-74. doi: 10.1038/clpt.2008.35. Clin Pharmacol Ther. 2008. PMID: 19238651

3

Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.

Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH. Tang SC, et al. Among authors: poller b. Int J Cancer. 2012 Jan 1;130(1):223-33. doi: 10.1002/ijc.26000. Epub 2011 Apr 7. Int J Cancer. 2012. PMID: 21351087 Free article.

4

P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.

Tang SC, Lankheet NA, Poller B, Wagenaar E, Beijnen JH, Schinkel AH. Tang SC, et al. Among authors: poller b. J Pharmacol Exp Ther. 2012 Apr;341(1):164-73. doi: 10.1124/jpet.111.186908. Epub 2012 Jan 11. J Pharmacol Exp Ther. 2012. PMID: 22238213

5

In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes.

Schmitt U, Kirschbaum KM, Poller B, Kusch-Poddar M, Drewe J, Hiemke C, Gutmann H. Schmitt U, et al. Among authors: poller b. Pharmacol Biochem Behav. 2012 Aug;102(2):312-20. doi: 10.1016/j.pbb.2012.04.002. Epub 2012 Apr 15. Pharmacol Biochem Behav. 2012. PMID: 22525746

6

In vitro-in vivo extrapolation method to predict human renal clearance of drugs.

Kunze A, Huwyler J, Poller B, Gutmann H, Camenisch G. Kunze A, et al. Among authors: poller b. J Pharm Sci. 2014 Mar;103(3):994-1001. doi: 10.1002/jps.23851. Epub 2014 Jan 13. J Pharm Sci. 2014. PMID: 24549735

7

Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.

Kunze A, Huwyler J, Camenisch G, Poller B. Kunze A, et al. Among authors: poller b. Drug Metab Dispos. 2014 Sep;42(9):1514-21. doi: 10.1124/dmd.114.058412. Epub 2014 Jul 2. Drug Metab Dispos. 2014. PMID: 24989890

8

Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins.

Kunze A, Poller B, Huwyler J, Camenisch G. Kunze A, et al. Among authors: poller b. Drug Metab Pers Ther. 2015 Sep;30(3):175-88. doi: 10.1515/dmdi-2015-0003. Drug Metab Pers Ther. 2015. PMID: 25996489

9

New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from in vitro hepatocyte and microsome data.

Riede J, Poller B, Umehara K, Huwyler J, Camenisch G. Riede J, et al. Among authors: poller b. Eur J Pharm Sci. 2016 Apr 30;86:96-102. doi: 10.1016/j.ejps.2016.02.022. Epub 2016 Mar 3. Eur J Pharm Sci. 2016. PMID: 26948853

10

Assessing the Risk of Drug-Induced Cholestasis Using Unbound Intrahepatic Concentrations.

Riede J, Poller B, Huwyler J, Camenisch G. Riede J, et al. Among authors: poller b. Drug Metab Dispos. 2017 May;45(5):523-531. doi: 10.1124/dmd.116.074179. Epub 2017 Mar 2. Drug Metab Dispos. 2017. PMID: 28254950

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

49 results

Search Page